- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14:02 | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Reports Telomir-1 Outperforms FDA-Approved Gold-Standard Iron Chelator Deferoxamine in Reducing Intracellular Iron in a Human Cell Line | 183 | ACCESS Newswire | New live-cell imaging data show that Telomir-1 markedly lowers intracellular iron levels at submicromolar concentrations in human keratinocytes, demonstrating potent cell penetration and iron-modulating... ► Artikel lesen | |
| 12:01 | Telomir Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| Mo | Telomir Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 23.10. | Telomir-1 shows promise in modulating cancer defense genes | 13 | Investing.com | ||
| 23.10. | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Resets Cancer's "Kill-and-Clean" Defense Systems in an Aggressive Prostate Cancer Model, Outperforming Rapamycin and Chemo | 244 | ACCESS Newswire | New findings highlight Telomir-1's impact on CASP8 and GSTP1, two critical genes that regulate cell death and glutathione-based detoxification pathways often disrupted in cancer. MIAMI, FLORIDA / ACCESS... ► Artikel lesen | |
| 22.10. | Telomir Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.10. | Telomir to Buy TELI | 2 | Baystreet.ca | ||
| 21.10. | Telomir Pharmaceuticals executes LOI for worldwide rights to Telomir-1 | 3 | Seeking Alpha | ||
| TELOMIR PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 21.10. | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Executes Binding LOI for Worldwide Rights to Telomir-1, Positioning the Company for Global Market Expansion and Value Growth | 245 | ACCESS Newswire | Unifying global IP rights and enabling up to $5 million in potential shareholder contributions, the agreement strengthens Telomir's foundation for partnerships, licensing, and long-term value creation.... ► Artikel lesen | |
| 14.10. | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Announces New Data Showing That Telomir-1 Kills Aggressive Pancreatic Cancer Cells, One of the Deadliest Forms of Cancer | 171 | ACCESS Newswire | Findings complement previously announced results in triple-negative breast cancer (TNBC) and prostate cancer models, highlighting Telomir-1's consistent impact on cancer cell survival pathways. MIAMI... ► Artikel lesen | |
| 14.10. | Telomir Pharmaceuticals, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 09.10. | Telomir Pharmaceuticals Touts Promising Action From Its Lead Breast Cancer Drug | 1 | Benzinga.com | ||
| 09.10. | Telomir stock soars after drug shows promise against aggressive breast cancer | 3 | Investing.com | ||
| 09.10. | Telomir-1 shows promise against triple-negative breast cancer | 4 | Investing.com | ||
| 09.10. | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Reports Discovery That Telomir-1 Selectively Kills Aggressive Triple-Negative Breast Cancer Cells | 216 | ACCESS Newswire | New findings show Telomir-1 shuts down cellular energy pathways and mitochondrial function in aggressive breast cancer cells, leading to cell death through iron-dependent regulation. MIAMI, FL / ACCESS... ► Artikel lesen | |
| 07.10. | Telomir stock soars after tumor suppressor gene reactivation results | 4 | Investing.com | ||
| 07.10. | Telomir-1 shows promise in reactivating tumor suppressor genes | 2 | Investing.com | ||
| 07.10. | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Announces New Findings in a Prostate Cancer Model Demonstrating Telomir-1 Also Resets DNA Methylation of Tumor Suppressor Genes Implicated in Two of the Most Persistent Challenges in Oncology-Metastasi | 218 | ACCESS Newswire | Findings show that Telomir-1 restores the body's natural tumor suppressor defenses by reversing abnormal DNA methylation of MASPIN and RASSF1A - genes that help block invasion, limit metastasis, and... ► Artikel lesen | |
| 07.10. | McCormick, Telomir Pharmaceuticals And 3 Stocks To Watch Heading Into Tuesday | 5 | Benzinga.com | ||
| 06.10. | Telomir Pharmaceuticals, Inc. - 8-K, Current Report | 3 | SEC Filings |
1 2 3 4 Weiter >>
77 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 96,60 | +2,93 % | Millionen für BioNTech und Evotec! Doch Medikamentenentwicklung kostet! Deshalb auf den Übernahmekandidaten NetraMark Aktie setzen!? | Nächste Erfolgsmeldung für NetraMark. Die KI des Unternehmens hat das nächste Biopharmaunternehmen überzeugt und wird immer mehr zum Übernahmekandidaten. Der neue Kunde will mit NetraAI seine klinische... ► Artikel lesen | |
| MODERNA | 22,700 | +3,87 % | Moderna überrascht - Startschuss zur Trendwende? | Zugegeben: Die Erwartungen der Wall Street an den Quartalsbericht des Corona-Impfstoff-Entwicklers waren niedrig. Sehr niedrig. Dennoch konnte Moderna die Prognosen deutlich übertreffen. Die Aktie gewinnt... ► Artikel lesen | |
| VALNEVA | 3,902 | +2,63 % | Valneva-Aktie sorgt für Aufmerksamkeit - steht eine größere Bewegung bevor?!! | ||
| CRISPR THERAPEUTICS | 46,400 | -2,93 % | CRISPR Therapeutics AG: CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310 Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering | -Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025- -Phase 1 clinical data for CTX310® demonstrate robust, dose-dependent reductions in... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,760 | +1,73 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights | Completed rolling Biologics License Application (BLA) submission seeking accelerated approval for lead candidate INO-3107; requested priority review
Expect... ► Artikel lesen | |
| OCUGEN | 1,142 | -0,22 % | Ocugen Provides Business Update with Third Quarter 2025 Financial Results | Phase 2/3 OCU410ST GARDian3 pivotal confirmatory trial is progressing toward 1H 2027 Biologics License Application (BLA) filing with 50% enrollment completed to date European Medicines Agency (EMA)... ► Artikel lesen | |
| VIKING THERAPEUTICS | 34,705 | -0,97 % | Here's Why Shares in Viking Therapeutics Shot Higher in October | ||
| BAVARIAN NORDIC | 25,450 | -0,93 % | BREAKING: Übernahme von Bavarian Nordic gescheitert - Aktie crasht | Die Aktionäre von Bavarian Nordic haben das Bieterkonsortium in Form von Nordic Capital und Permira abblitzen lassen. Das Investorenduo konnte trotz des zuvor erhöhten Übernahmeangebotes nicht die dafür... ► Artikel lesen | |
| GERON | 1,070 | +0,33 % | Geron justiert Rytelo-Strategie neu: Fokus auf früheren Therapie-Einsatz | ||
| IMMUNITYBIO | 1,786 | -3,09 % | ImmunityBio GAAP EPS of -$0.07 beats by $0.04, revenue of $32.06M beats by $0.18M | ||
| IOVANCE BIOTHERAPEUTICS | 2,190 | -4,12 % | Down 75% in 12 Months, Can Iovance Biotherapeutics Stock Turn Things Around? | ||
| ZAI LAB LTD ADR | 19,200 | +1,05 % | ZAI LAB (09688): GRANT OF SHARE OPTIONS AND RESTRICTED SHARE UNITS | ||
| VERASTEM | 7,000 | -4,11 % | Verastem stock price target raised to $14 from $13 at RBC Capital | ||
| APELLIS PHARMACEUTICALS | 16,976 | +0,81 % | Apellis reports SYFOVRE delays GA lesion growth by 1.5 years | ||
| GRAIL | 73,40 | +1,94 % | Grail war NASDAQ-Tagessieger | Der kalifornische Krebstest-Entwickler hat die vor zwei Wochen gefahrene Attacke des Shortsellers Ningi Research zunächst offenbar abgeschüttelt. Der Leerverkäufer hatte Zweifel am späteren Erfolge... ► Artikel lesen |
TELOMIR PHARMACEUTICALS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -1,06 % bei einem Aktienkurs von 1,395 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TELOMIR PHARMACEUTICALS INC finden Sie auf Wallstreet Online.